

3rd Quarter 2024 Results¹

3rd Quarter 2024 Sales

Worldwide increased ▲
\$22.5B **5.2%**

Excluding acquisitions /
divestitures on an
operational basis Worldwide increased ▲
5.4%*


Diluted earnings per share³

Decreased ▼
\$1.11 **(34.3)%**

Adjusted diluted earnings per share*

Decreased ▼
\$2.42 **(9.0)%**

Acquired IPR&D impacting results by ~1,900 basis points




Joaquin Duato
Chairman & Chief
Executive Officer
Johnson & Johnson

“Johnson & Johnson’s strong results in the third quarter reflect the unique breadth of our business and commitment to delivering the next wave of healthcare innovation. During the quarter, we advanced our pipeline with regulatory approvals for TREMFYA and RYBREVANT, submitted an IDE for our general surgery robotic system, OTTAVA, and launched VELYS Spine and Shockwave E⁸ IVL Catheter, further strengthening our confidence in our near-and long-term growth targets.”

\$14.6 billion **Worldwide Innovative Medicine sales**
Innovative Medicine worldwide reported sales increased 4.9% or 6.3% operationally².
Primary operational drivers:



\$7.9 billion **Worldwide MedTech sales**
MedTech worldwide reported sales increased 5.8% or 6.4% operationally².
Primary operational drivers:



For full financial data, non-GAAP reconciliations and cautionary statements, please refer to Johnson & Johnson’s earnings release issued on October 15, 2024 available at <https://www.investor.jnj.com/financials/quarterly-results/default.aspx>

*Non-GAAP financial measure; non-GAAP financial measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures.

¹ Reflects continuing operations of Johnson & Johnson.

² Non-GAAP measure; excludes the impact of translational currency.

³ Diluted earnings per share results impacted by a one-time special charge and acquired IPR&D.

Note: Values may be rounded.

Caution Concerning Forward-Looking Statements: This document contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding future operating and financial performance. You are cautioned not to rely on these forward-looking statements, which are based on current expectations of future events. For important information about the risks and uncertainties that could cause actual results to vary materially from the assumptions, expectations, and projections expressed in any forward-looking statements, review the “Note to Investors Concerning Forward-Looking Statements” included in the Johnson & Johnson earnings release issued on October 15, 2024 as well as the most recently filed Johnson & Johnson Reports on Forms 10-K and 10-Q. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

Johnson & Johnson